FDA Approves New Immunotherapy for Endometrial Cancer FDA Approves New Immunotherapy for Endometrial Cancer
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Media News)
Source: Roche Media News - April 23, 2021 Category: Pharmaceuticals Source Type: news

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy
Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. (Source: Roche Investor Update)
Source: Roche Investor Update - April 23, 2021 Category: Pharmaceuticals Source Type: news

Tislelizumab Bests Docetaxel in NSCLC Tislelizumab Bests Docetaxel in NSCLC
The new immunotherapy prolonged overall survival when compared with docetaxel in patients with locally advanced non-small cell lung cancer (NSCLC).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 22, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Expert Consensus on Neoadjuvant Immunotherapy for NSCLC Expert Consensus on Neoadjuvant Immunotherapy for NSCLC
A new expert consensus provides guidance regarding the use of neoadjuvant immunotherapy in NSCLC.Translational Lung Cancer Research (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 22, 2021 Category: Surgery Tags: Hematology-Oncology Journal Article Source Type: news

A new method for fighting 'cold' tumors
(University of Colorado Anschutz Medical Campus) Researchers Michael Knitz and radiation oncologist and University of Colorado Cancer Center member Sana Karam, MD, PhD, address cold tumors in new research published this week in the Journal for ImmunoTherapy of Cancer. Working with mouse models in Karam's specialty area of head and neck cancers, Knitz and Karam studied the role of T cells in tumor treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 22, 2021 Category: International Medicine & Public Health Source Type: news

Antibiotics May Prolong PFS in HCC Patients on Immunotherapy Antibiotics May Prolong PFS in HCC Patients on Immunotherapy
Taking antibiotics 30 days before or after starting an immune checkpoint inhibitor was associated with a benefit in progression-free survival (PFS) for patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Opdivo Plus Chemotherapy Approved for Treatment of Gastric Cancer
FDA granted Opdivo first approval of immunotherapy for first - line treatment of advanced or metastatic gastric cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 20, 2021 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, FDA Approvals, Source Type: news

U.S. FDA Approves ALK's Ragwitek (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis
ROUND ROCK, Texas, April 19, 2021 /PRNewswire/ -- ALK (ALKB: DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the diagnosis and treatment of allergies, announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 19, 2021 Category: Drugs & Pharmacology Source Type: news

MyMD Pharmaceuticals completes merger with South Jersey medical diagnostics firm
The new combined company will focus on developing immunotherapies. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 19, 2021 Category: American Health Authors: John George Source Type: news

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status
PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial of this patient population1 U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 16, 2021 Category: Drugs & Pharmacology Source Type: news

Chronic Adverse Effects From Anti - PD - 1 Immunotherapies Common
About 43 percent of patients who receive anti - PD1 therapy for advanced melanoma have chronic immune - related adverse effects (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 16, 2021 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news

FDA Approves Frontline Immunotherapy for Gastric Cancers FDA Approves Frontline Immunotherapy for Gastric Cancers
The approval marked a first for an immunotherapy in patients with gastric cancers.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 16, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
THOUSAND OAKS, Calif., April 16, 2021 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prim... Biopharmaceuticals, Oncology, Mergers & Acquisitions Amgen, Five Prime Therapeutics, immunotherapy, targeted therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 16, 2021 Category: Pharmaceuticals Source Type: news

Chronic Adverse Effects From Anti-PD-1 Immunotherapies Common
FRIDAY, April 16, 2021 -- Chronic immune-related adverse effects after adjuvant treatment with anti-programmed cell death 1 (anti-PD-1) immunotherapies for melanoma are more common than previously thought, according to a study published online March... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2021 Category: Pharmaceuticals Source Type: news

Tebentafusp improves OS: A First in Metastatic Uveal Melanoma Tebentafusp improves OS: A First in Metastatic Uveal Melanoma
First-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in a phase 3 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Long-term survival rates for immunotherapies could be misinterpreted
(Vanderbilt University Medical Center) Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

NCCN Foundation announces awards for rising cancer research leaders
(National Comprehensive Cancer Network) National Comprehensive Cancer Network announces recipients of 2021 NCCN Foundation Young Investigator Awards; projects from early-career investigators to advance research in cancer prevention, racial disparities in screening, immunotherapy, new insights in radiotherapy, and CAR T-cell therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

Study: New approach may boost prostate cancer immunotherapies
(Cedars-Sinai Medical Center) Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body's immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the US. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 15, 2021 Category: International Medicine & Public Health Source Type: news

Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation
(University of Pennsylvania School of Medicine) Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2021 Category: Cancer & Oncology Source Type: news

Sequence of immunotherapy matters
(Source: ScienceNOW)
Source: ScienceNOW - April 15, 2021 Category: Science Authors: Erkes, D. A. Tags: twis Source Type: news

Diabetes drug shows potential in fighting cancer
(Massachusetts General Hospital) Phenformin, in combination with immunotherapies like PD-1 immune checkpoint inhibitors, shows greater promise than phenformin or metformin alone. A clinical trial is under way at MGH to evaluate the use of phenformin with an inhibitor of the BRAF-mutated gene, present in roughly half of all melanomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Adverse Reactions to Immunotherapy Can Appear After a Year Adverse Reactions to Immunotherapy Can Appear After a Year
Some cancer patients receiving anti-PD-1 immunotherapy may tolerate the drug well for months but then develop a serious immune-related adverse reaction.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 13, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC
For patients with resectable non –small cell lung cancer (NSCLC) tumors, adding immunotherapy to platinum-based chemotherapy improved pathologic complete response (pCR) rates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

AI and immunotherapy: Taking the next step
(Case Western Reserve University) Researchers from Case Western Reserve University, New York University (NYU), and University Hospitals in Cleveland have been awarded a five-year, $3 million National Cancer Institute grant to develop and apply AI tools for predicting which lung cancer patients will respond to immunotherapy. This is first time they'll test those tools during an ongoing clinical trial, the next step toward their own clinical trials that would allow physicians to apply the tools with participating patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2021 Category: International Medicine & Public Health Source Type: news

Exercise benefit in breast cancer linked to improved immune responses
(Massachusetts General Hospital) Physical exercise increases levels of cancer-fighting immune cells in animal models of breast cancer and slows the growth of tumors. In addition to lowering risk of developing cancer, structured exercise programs could help improve therapy for females with existing breast tumors. Exercise may also significantly improve treatment of breast cancer with immunotherapy drugs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2021 Category: International Medicine & Public Health Source Type: news

Study reveals cancer immunotherapy patients at most risk of life-threatening side effects
(Massachusetts General Hospital) Immune checkpoint inhibitors boost a patient's immune response against cancer cells, but they can cause potentially life-threatening side effects in some individuals. New research may help clinicians determine which patients are most at risk. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

Early findings show new drug could be ‘gamechanging’ for brain cancer treatment
Using ipatasertib, researchers say some brain cancers could potentially be made vulnerable to immunotherapy agentTwo people with advanced brain cancer of the sort that led to the death of the MP Tessa Jowell have responded well in a small trial to an experimental combination of chemo and immunotherapy drugs. In one case, the life-threatening tumour seems to have disappeared.Doctors at the Institute of Cancer Research and the Royal Marsden hospital in London cautioned that this was very early research but said it was unusual to have such a good response in patients in an early trial.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - April 11, 2021 Category: Science Authors: Sarah Boseley Tags: Cancer research Medical research Health Science Society Source Type: news

Yale Cancer Center study shows novel immunotherapy approach to fight melanoma
(Yale University) In a new study led by Yale Cancer Center, researchers have advanced a tumor-targeting and cell penetrating antibody that can deliver payloads to stimulate an immune response to help treat melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2021 Category: Cancer & Oncology Source Type: news

Study provides new insights into resistance to immune checkpoint inhibitors
(Yale University) New research by Yale Cancer Center shows insights into modeling resistance to immune checkpoint inhibitors, a form of cancer immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 11, 2021 Category: Cancer & Oncology Source Type: news

Level of chromosomal abnormality in lung cancer may predict immunotherapy response
(Dana-Farber Cancer Institute) Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma
(University of California - Los Angeles Health Sciences) Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA found using a bilateral attack achieves a more robust defense and helps avoid relapse. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

Negative Results When Immunotherapy Was Added Onto Radiation Negative Results When Immunotherapy Was Added Onto Radiation
A phase 3 trial investigating the addition of immunotherapy to avelumab onto chemoradiotherapy in patients with head and neck cancer was stopped early.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Genes and immune cells predict immunotherapy success in bladder cancer
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study published in Clinical Cancer Research, the team uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors, drugs that help the body's immune system recognize and attack cancerous cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 9, 2021 Category: Cancer & Oncology Source Type: news

Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer...
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study...(PRWeb April 09, 2021)Read the full story at https://www.prweb.com/releases/resistance_to_immunotherapy_in_patients_with_urothelial_bladder_cancer_is_traced_to_specific_sets_of_immune_cells/prweb17850269.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 9, 2021 Category: Pharmaceuticals Source Type: news

Imvax Appoints Sean Hemingway as Chief Operating Officer
Imvax expands its leadership team as the emerging biotech company continues to grow PHILADELPHIA, April 8, 2021 -- (Healthcare Sales & Marketing Network) -- Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients wit... Biopharmaceuticals, Oncology, Personnel Imvax, neo-antigen immunotherapy, glioblastoma multiforme (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 8, 2021 Category: Pharmaceuticals Source Type: news

MD Anderson and TriSalus Life Sciences announce strategic research collaboration to evaluate treatment of solid tumors
(University of Texas M. D. Anderson Cancer Center) MD Anderson and TriSalus announced a strategic research collaboration to evaluate the treatment of liver and pancreas tumors with the investigational therapy SD-101 in combination with immunotherapy using a novel delivery approach. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2021 Category: International Medicine & Public Health Source Type: news

Recruiting T cells in cancer immunotherapy
(Source: ScienceNOW)
Source: ScienceNOW - April 8, 2021 Category: Science Authors: Yost, K. E., Chang, H. Y., Satpathy, A. T. Tags: perspective Source Type: news

NIDCR's Spring 2021 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Spring 2021 E-Newsletter In this issue: NIDCR News Funding Opportunities & Related Notices NIH/HHS News Subscribe to NICDR News Science Advances   Grantee News   NIDCR News NIDCR & NIH Stand Against Structural Racism NIDCR Director Rena D’Souza, DDS, MS, PhD, said in a statement that there is no place for structural racism in biomedical research, echoing remarks from NIH Director Francis Collins, MD, PhD, in his announcement of a new NIH ...
Source: NIDCR Science News - April 7, 2021 Category: Dentistry Source Type: news

Cancer discovery could revive failed treatments for solid tumors
(University of Virginia Health System) New research could rescue once-promising immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer, that ultimately failed in human clinical trials. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 6, 2021 Category: Cancer & Oncology Source Type: news

Delivery of Oncolytic Immunotherapy by MSCs Enhances CAR-T Cell Anti-Tumor Activity
Katie McKenna will discuss how oncolytic viral therapy enhances CAR-T cell killing of cancer cells. (Source: The Scientist)
Source: The Scientist - April 5, 2021 Category: Science Tags: Sponsored Webinars Source Type: news

NIDCR Science News - April 2021
Having trouble viewing this email? View it as a Web page. A monthly update of NIDCR-supported science advances, as reported by grantee institutions and NIH. SARS-CoV-2 May Infect the Mouth NIDCR-led study points to role for saliva in spread of virus NIDCR • March 25, 2021 A Safe Space in the Dental Clinic Making dental visits more soothing for children with autism NIDCR • March 23, 2021 How Fungus Finds A Foothold in the Mouth Overactive ...
Source: NIDCR Science News - April 5, 2021 Category: Dentistry Source Type: news

Software package enables deeper understanding of cancer immune responses
(Johns Hopkins Medicine) Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center have developed DeepTCR, a software package that employs deep-learning algorithms to analyze T-cell receptor (TCR) sequencing data. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2021 Category: International Medicine & Public Health Source Type: news

NHS patients to be offered cancer treatment at home
Specialist nurses from top cancer centre The Christie NHS Foundation Trust in Manchester are already offering at-home chemotherapy and immunotherapy to 250 patients a day. (Source: the Mail online | Health)
Source: the Mail online | Health - April 3, 2021 Category: Consumer Health News Source Type: news

Combo Therapy Helps Beat a Common Childhood Leukemia
Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new research suggests. (Source: WebMD Health)
Source: WebMD Health - April 2, 2021 Category: Consumer Health News Source Type: news

Adding in Stem Cell Therapy Helps Beat a Common Childhood Leukemia
FRIDAY, April 2, 2021 -- Combining stem cell transplants with cutting-edge immunotherapy prevents leukemia relapses in young people and improves their chances of survival, new research suggests. Acute lymphoblastic leukemia is the most common... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 2, 2021 Category: General Medicine Source Type: news

Researchers devise more efficient, enduring CAR gene therapy to combat HIV
FINDINGSA UCLA research team has shown that using a truncated form of the CD4 molecule as part of a gene therapy to combat HIV yielded superiorand longer-lastingresults in mouse models than previous similar therapies using the CD4 molecule.This new approach to CAR T gene therapy — a type of immunotherapy that involves genetically engineering the body ’s own blood-forming stem cells to create HIV-fighting T cells— has the potential to not only destroy HIV-infected cells but to create “memory cells” that could provide lifelong protection from infection with the virus that causes AIDS.BACKGROUNDC...
Source: UCLA Newsroom: Health Sciences - April 1, 2021 Category: Universities & Medical Training Source Type: news

Low-calorie diet and mild exercise improve survival for young people with leukemia
In some cancers, including leukemia in children and adolescents, obesity can negatively affect survival outcomes. Obese young people with leukemia are 50% more likely to relapse after treatment than their lean counterparts.Now,a study led by researchers at UCLA and Children’s Hospital Los Angeles has shown that a combination of modest dietary changes and exercise can dramatically improve survival outcomes for those with acute lymphoblastic leukemia, the most common childhood cancer.The researchers found that patients who reduced their calorie intake by 10% or more and adopted a moderate exercise program imm...
Source: UCLA Newsroom: Health Sciences - April 1, 2021 Category: Universities & Medical Training Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

SITC Announces Two Spatial Technology Awards for Early Career...
The Society for Immunotherapy of Cancer (SITC) is committed to championing the next generation of cancer immunotherapy experts through dedicated support of novel research. SITC is pleased to offer...(PRWeb April 01, 2021)Read the full story at https://www.prweb.com/releases/sitc_announces_two_spatial_technology_awards_for_early_career_scientists_to_advance_cancer_immunotherapy_research/prweb17841412.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 1, 2021 Category: Pharmaceuticals Source Type: news